Every 10-Q that Black Hawk Acquisition Corporation (BKHA) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow BKHA and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full BKHA filings page.
Black Hawk Acquisition Corp. (BKHA) reported net income of $1,074,736 for the three months ended August 31, 2026, including a $1,015,988 gain from Vesicor’s debt forgiveness. At August 31, 2026, it had $12,052 in cash, a $2,294,124 working-capital deficit and $25,993,300 in its trust account. Management said its liquidity and the risk of not completing a business combination within the permitted period raise substantial doubt about its ability to continue as a going concern. Nasdaq closed its listing-compliance matter after Black Hawk’s market value of listed securities was at least $50,000,000 for 10 consecutive business days.
The proposed merger values Vesicor at a $70 million pre-money equity value and remains subject to shareholder, regulatory and other closing conditions. A shareholder meeting is scheduled for October 13, 2026, and completion is expected by the fourth quarter of 2026. September agreements with Meteora include a forward transaction for up to 1,350,000 shares, subject to upward adjustment; a best-efforts non-redemption arrangement for up to 2,124,077 shares; and a standby facility allowing PubCo to sell up to $200.0 million of shares, subject to conditions and required registration effectiveness. Ordinary advances under the facility are generally priced at 97% of the applicable market price.
Black Hawk Acquisition Corporation, a SPAC, reported modest profitability for the quarter ended May 31, 2026, driven by interest on its trust investments. Net income was $88,929 for the quarter and $228,734 for the first six months, with $25.3 million held in the Trust Account and $11,583 of cash outside it.
The company has a working capital deficit of $2.69 million and management concluded that substantial doubt exists about its ability to continue as a going concern unless it completes a business combination within the extended period ending December 22, 2026. A Business Combination Agreement with Vesicor Therapeutics values Vesicor at $70 million, with all Vesicor equity rolling into the combined company, but closing remains uncertain.
Shareholders redeemed 4,775,923 public shares for about $51.0 million, leaving 2,124,077 public shares outstanding and approximately $22.7 million initially in trust, supplemented by later extension deposits. On March 31, 2026 Nasdaq notified Black Hawk that its market value of listed securities had fallen below the $50 million minimum, giving it until September 28, 2026 to regain compliance. After quarter-end, Vesicor forgave $1,015,988 of advances, reducing amounts due to the target.
Black Hawk Acquisition Corporation reported unaudited results for the quarter ended February 28, 2026, reflecting its ongoing status as a SPAC preparing for an initial business combination with Vesicor Therapeutics.
Total assets were $24.8 million, including $24.6 million of investments in the Trust Account, while cash outside the trust was $178,407 and working capital showed a deficit of $2.1 million. The company recorded net income of $139,805, driven mainly by $213,442 of interest on trust investments, partially offset by general and administrative costs, related party fees, and interest expense.
Shareholders approved extensions that allow monthly deadline pushes for completing a business combination through December 22, 2026, funded by $150,000 monthly deposits, after 4,775,923 public shares were redeemed for about $51.0 million. Management cites substantial doubt about the company’s ability to continue as a going concern if a transaction is not completed within the combination period, and it has received a Nasdaq notice due to market value of listed securities falling below the $50 million requirement.
Black Hawk Acquisition Corp. (BKHA) filed its 10-Q for the quarter ended August 31, 2025, reporting modest non‑operating profit while advancing its pending merger. Q3 net income was $154,401, driven mainly by interest, with nine‑month net income of $1,333,322.
The Trust Account stood at $23,296,572 after holders of 4,775,923 public shares redeemed approximately $51.0 million at about $10.68 per share. Following redemptions, 2,124,077 public shares remain outstanding. The company approved monthly extensions through December 22, 2026 and deposited $150,000 per month in July, August, and September to extend the deadline to October 22, 2025.
Black Hawk signed a Business Combination Agreement with Vesicor Therapeutics, valuing Vesicor at a $70 million pre‑money equity value, with all Vesicor equity rolling into the combined company, subject to approvals. Liquidity remains tight with $15,000 cash and a working capital deficit of $901,638, and management disclosed substantial doubt about the ability to continue as a going concern. The company recorded a $350,000 6% convertible note in June and, subsequently on September 23, 2025, issued another up to $350,000 at 10%. A deferred underwriting fee of $2,415,000 remains payable upon closing a business combination.